ISSN: 2375-3900
American Journal of Pharmacy and Pharmacology  
Manuscript Information
 
 
Effect of Highly Active Antiretroviral Therapy (HAART) on Renal Functions among Persons Living with HIV and AIDS (PLWHA) in Sokoto, North Western Nigeria
American Journal of Pharmacy and Pharmacology
Vol.1 , No. 3, Publication Date: Aug. 20, 2014, Page: 23-27
1242 Views Since August 20, 2014, 876 Downloads Since Apr. 14, 2015
 
 
Authors
 
[1]    

Mainasara A. S., Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.

[2]    

Isah B. A., Department of Community Health, College of Health Sciences Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.

[3]    

Ahmed A. Y., Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.

[4]    

Erhabor O., Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.

 
Abstract
 

HIV/AIDS is a global public health problem. As of 2012, approximately 35.3 million people were living with HIV/AIDS worldwide. The aim of this descriptive comparative was to determine the effect Highly Active Antiretroviral Therapy (HAART) of Stavudine, Lamivudine and Nevirapine on renal function of Persons Living with HIV and AIDS (PLWHA) accessing care at Usmanu Danfodiyo University Teaching Hospital Sokoto, North Western Nigeria. The level of total protein, albumin and creatinine were determined in 90 HIV- infected subjects aged 20-50 years. Thirty HIV-seronegative, age and gender- matched individuals were monitored as controls. Seventy of the HIV/AIDS infected patients were on HAART while 20 of the patients were yet to commence HAART. The level of the serum total protein and albumin observed among HIV infected subjects (on HAART and those not on HAART) and HIV negative controls were not significant (p > 0.05). Significant difference was observed in serum creatinine of HIV infected subjects on HAART and those not on HAART (p = 0.02). The results show that HAART of Stavudine, Lamivudine and Nevirapine improves renal creatinine clearance functions among the HIV positive clients but have no effect on levels of total protein and albumin.


Keywords
 

HIV, HAART, Renal Function, Liver Function


Reference
 
[01]    

Greener R. AIDS & Macroeconomics Impact” in S. Forsyth (ed.) States of the Art: AIDS and Economics IAEN 2002: 49-55.

[02]    

Brooks G.F, Carnoll K.C, Janet. S Butel, Morse S.A, Mietne T.A. “Jawetz, Melnick S. Adelberg’s Medical Microbiology” McGraw-Hill Companies North American. 25th Edition 2010: 406-407.

[03]    

Lu TC, Ross M. HIV-associated nephropathy: a brief review. Mt Sinai J Med 2005; 72(3):193-199.

[04]    

Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, Johnson L, Fisher M, Holt SG, Bhagani S, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis 2008; 46(8):1282-1289.

[05]    

Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE, et al . The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66(3):1145-1152.

[06]    

Winston JA, Klotman ME, Klotman PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 1999; 55(3):1036-1040.

[07]    

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Panel on Clinical Practices for Treatment of HIV "Ann. Intern. Med 2002; 137: 381–433.

[08]    

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007; 8(2):96-104.

[09]    

When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373(9672):1352-1363.

[10]    

Anderson NL and Anderson NG. High Resolution Two Dimensional Electrophoresis of Human plasma proteins’’ Proceeding of the National Academy of Sciences 1977; 74(12): 5421-5425.

[11]    

Fauci AS, Lane HC. Human immunodeficiency virus Disease; AIDS and related Disorders. In: Kasper DL, Fauci AS, et al. editors. Harrison's Principle of Internal Medicine. 16th ed. New York: McGraw-Hill Co; 2005:1076-1079.

[12]    

Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch P. Effects of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus co-infection. Lancet 2003;362:1708-1713

[13]    

Chijioke A. Nwauche, Osaro Erhabor, Oseikhuemen A Ejele, Chris I Akani. Adherence to antiretroviral therapy among HIV-infected subjects in a resource - limited setting in the Niger Delta of Nigeria. African Journal of Health Sciences 2006;13 (3-4):13-17.

[14]    

NPC/FRN (2006). Nigeria Population Commission, Federal Republic of Nigeria. Special FGN. Gazette number 23 on the 2006 Population Census.

[15]    

Ogundahunsi, O. A, Akinyele, Oyegunle, V. A, Ambali, A. A, Mbacham, W. The prevalence of renal disorder in HIV/AIDs patients on HAART. Int J Biomed & Health. Sci 2008; 4 (1): 1-4.

[16]    

Ugwuja EI. An assessment of renal functions in HIV-seropositive patients at Ebonyi State University Teaching Hospital, Abakaliki, South Eastern Nigeria. International Journal of Biomedical and Health Sciences 2010; 210-213.

[17]    

Olawumi HO and Olatunji PO. The value of serum albumin in pre-treatment assessment and monitoring of therapy in HIV/AIDS patients. British HIV Association, HIV Medicine 2006; 72006: 351–355.

[18]    

Emem P, Arogunde F, Sanusi A, Adelusola K, Wokoma F and Akinsola A. Renal disease in HIV seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephro Dialysis transplantation 2008; 23 (2): 741-746.

[19]    

Isaac M K, Loren M D, and Judith A.H. Late disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. Journal of immune deficiency syndrome 1999; 52(2): 280.

[20]    

Levin J, Kalayjian R, Machekano R, Crane H, Kitahata M, Multani A, Salata R, Willig J, Kestanbaum B, Krishasami Z, and Rodriguez B. HAART is associated with improved kidney function in patients with impaired kidney function at baseline but was associated with slight worsening of kidney function in patients with normal baseline kidney function. Conference on Retroviruses and Opportunistic Infections San Francisco CA February 2010: 16-19.

[21]    

Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD . Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18(3):541-546.

[22]    

Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res 2010; 8(7):504-509.

[23]    

Côté HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006; 11(1):79-86.





 
  Join Us
 
  Join as Reviewer
 
  Join Editorial Board
 
share:
 
 
Submission
 
 
Membership